BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 30445057)

  • 1. Nasal allergen-neutralizing IgG
    Shamji MH; Kappen J; Abubakar-Waziri H; Zhang J; Steveling E; Watchman S; Kouser L; Eifan A; Switzer A; Varricchi G; Marone G; Couto-Francisco NC; Calderon M; Durham SR
    J Allergy Clin Immunol; 2019 Mar; 143(3):1067-1076. PubMed ID: 30445057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy.
    Shamji MH; Larson D; Eifan A; Scadding GW; Qin T; Lawson K; Sever ML; Macfarlane E; Layhadi JA; Würtzen PA; Parkin RV; Sanda S; Harris KM; Nepom GT; Togias A; Durham SR
    J Allergy Clin Immunol; 2021 Oct; 148(4):1061-1071.e11. PubMed ID: 33819508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
    Nouri-Aria KT; Wachholz PA; Francis JN; Jacobson MR; Walker SM; Wilcock LK; Staple SQ; Aalberse RC; Till SJ; Durham SR
    J Immunol; 2004 Mar; 172(5):3252-9. PubMed ID: 14978133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.
    Shamji MH; Ljørring C; Francis JN; Calderon MA; Larché M; Kimber I; Frew AJ; Ipsen H; Lund K; Würtzen PA; Durham SR
    Allergy; 2012 Feb; 67(2):217-26. PubMed ID: 22077562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
    Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
    Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
    Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
    J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
    Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
    Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells.
    Scadding GW; Shamji MH; Jacobson MR; Lee DI; Wilson D; Lima MT; Pitkin L; Pilette C; Nouri-Aria K; Durham SR
    Clin Exp Allergy; 2010 Apr; 40(4):598-606. PubMed ID: 20184605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradermal grass pollen immunotherapy increases T
    Slovick A; Douiri A; Muir R; Guerra A; Tsioulos K; Hay E; Lam EPS; Kelly J; Peacock JL; Ying S; Shamji MH; Cousins DJ; Durham SR; Till SJ
    J Allergy Clin Immunol; 2017 Jun; 139(6):1830-1839.e13. PubMed ID: 27773851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy.
    Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M
    Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of IgE-Allergen-CD23 Complex Changes in Children Treated with Subcutaneous Immunotherapy for Japanese Cedar Pollinosis.
    Asaumi T; Sato S; Yanagida N; Matsuhara H; Kobayashi S; Fukano C; Ohashi-Doi K; Ebisawa M
    Int Arch Allergy Immunol; 2021; 182(3):190-194. PubMed ID: 33032294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
    Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression.
    Pilette C; Nouri-Aria KT; Jacobson MR; Wilcock LK; Detry B; Walker SM; Francis JN; Durham SR
    J Immunol; 2007 Apr; 178(7):4658-66. PubMed ID: 17372025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy.
    Pfaar O; Urry Z; Robinson DS; Sager A; Richards D; Hawrylowicz CM; Bräutigam M; Klimek L
    Allergy; 2012 Feb; 67(2):272-9. PubMed ID: 22107266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge.
    Scadding GW; Eifan AO; Lao-Araya M; Penagos M; Poon SY; Steveling E; Yan R; Switzer A; Phippard D; Togias A; Shamji MH; Durham SR
    Allergy; 2015 Jun; 70(6):689-96. PubMed ID: 25773990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with a Phleum pratense allergen extract induces an immune response to a grass-mix allergen extract.
    Martínez-Cócera C; Sastre J; Cimarra M; Quirce S; Fernández-Rivas M; Enríquez-Matas A; Rodríguez-Alvarez M; Martín S
    J Investig Allergol Clin Immunol; 2010; 20(1):13-9. PubMed ID: 20232769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
    Klimek L; Schendzielorz P; Pinol R; Pfaar O
    Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.